Drug Search Results
Using advanced filters...
Advanced Search [+]

LY-041001

Alternative Names: ly-041001, ly041001, ly 041001
Latest Update: 2023-10-18
Latest Update Note: Clinical Trial Update

Product Description

U-500R Insulin for Type 2 Diabetes

Mechanisms of Action: INSR Binder

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Inhalant

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Type 2 Diabetes

Phase 3: Type 2 Diabetes|Type 1 Diabetes|Asthma|Chronic Obstructive Pulmonary Disease|Tobacco Use Disorder

Phase 2: Type 2 Diabetes|Type 1 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

B5K-EW-IBHG

P1

Terminated

Type 2 Diabetes

2017-05-25

VIVID

P3

Completed

Type 2 Diabetes

2017-05-09

B5K-US-IBHC

P4

Completed

Type 2 Diabetes

2014-05-01

H7U-MC-IDBA

P3

Completed

Type 2 Diabetes

2008-06-01

63%

Recent News Events

Date

Type

Title